AdAlta (ASX:1AD), a clinical stage biotechnology company developing novel therapeutic products from its i-body platform, announced that a second Japanese patent relating to their lead program, AD-214, has been granted by the Japanese Patent Office.
This patent extends the range and diversity of sequences analogous to AD-214 that are protected and is valid until 8 January 2036.
This is the second patent granted in Japan for AD-214, and patents also exist in the U.S., Europe, China, Australia, India, Hong Kong and Singapore.
AdAlta is collaborating with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) and GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging).
Following the announcement, shares of AdAlta were unchanged at $0.040.